key: cord-0840620-tl5rjgdd
authors: Toh, Yee-Huan; Huang, Yu-Weng; Chang, Yo-Chen; Chen, Yi-Ting; Hsu, Ya-Ting; Lin, Guang-Huey
title: Reactivity of human antisera to codon optimized SARS-CoV2 viral proteins expressed in Escherichia coli
date: 2021-03-09
journal: Tzu Chi Med J
DOI: 10.4103/tcmj.tcmj_189_20
sha: 55bf337a20c364e051b674492efb6b1f4aa524e9
doc_id: 840620
cord_uid: tl5rjgdd

OBJECTIVE: The coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV2 virus continues to pose a serious threat to public health worldwide. The development of rapid diagnostic kits can assist the Tzu Chi Foundation in supporting global volunteers working to provide relief during the current pandemic. MATERIALS AND METHODS: In this study, nucleotide sequences derived from publicly available viral genome data for several domains of the SARS-CoV2 spike and nucleocapsid (N) proteins were chemically synthesized, with codon optimization for Escherichia coli protein expression. No actual viral particles were involved in these experiments. The synthesized sequences were cloned into an E. coli expression system based on pQE80L, and expressed viral proteins were subsequently purified using Ni-affinity chromatography. Western blotting was conducted using human antiviral sera to assess the response of codon-modified viral proteins to COVID-19 patient sera. RESULTS: N protein was expressed in amounts large enough to support large-scale production. The N-terminal domain, receptor-binding domain (RBD), Region 3, and the S2 domain were expressed in small but sufficient amounts for experiments. Immunoblotting results showed that anti-N IgG and anti-N IgM antibodies were detected in most patient sera, but only 60% of samples reacted with the recombinant RBD and S2 domain expressed by E. coli. CONCLUSION: The results indicated that codon-optimized SARS-CoV2 viral proteins can be expressed in E. coli and purified for rapid antibody detection kit preparation, with the codon-optimized N protein, RBD, and S2 protein demonstrating the most potential.

T he current coronavirus disease 2019 (COVID-19) pandemic caused by the novel SARS-CoV2 coronavirus was first detected in China during late 2019 and has rapidly spread around the world since then. The Tzu Chi Foundation has around 100 service branches worldwide with more than 10 million volunteers, and these volunteers are exposed to high risk as they work to provide relief to those in need during the current pandemic. To provide safe working environments, accurate and rapid testing kits to identify uninfected, infected, and recovered populations are necessary, and here we describe the establishment of an Escherichia coli-based viral protein expression and purification platform that can produce codon-optimized SARS-CoV2 viral proteins for use in rapid antibody/antigen diagnostic kits. key functional role in ACE2 binding and is also important for neutralizing host antibody production as well. The N protein, which binds the RNA of the viral genome, is the most abundantly produced viral protein and is highly immunogenic during viral infection [2] .

E. coli expression systems are distinguished for their ease of use and convenience, but have a key limitation in that posttranslational modification is absent, and this can impact the expression of proteins that require posttranslational modification. Certainly, protein expression systems that can perform posttranslational modification have been established in different eukaryotic cells, including Saccharomyces cerevisiae [4, 5] . Chinese hamster ovary cells [6] , and baculovirus expression systems [7] . These systems have an advantage in that protein phosphorylation and glycosylation are achievable, but E. coli expression systems are superior in terms of the ability to rapidly produce large amounts of viral proteins that can serve as antigens for diagnostic tests.

Comparative analysis of 13 different coronaviruses regarding preferred nucleotides, codon bias, nucleotide changes at the third position (NT3s), synonymous codon usage, and relative synonymous codon usage has revealed that 18 amino acids have preferred codons, of which eight of these were over-biased [8] . Since different organisms have their own bias regarding usage of the 61 available codons, when E. coli systems are forced to express proteins with "rare" codons under heterologous gene expression conditions, this can result in low expression levels or truncated protein products due to premature termination of protein translation. This issue of codon bias can be overcome through two possible approaches: the first involves cotransformation with a plasmid that encodes the transfer RNAs corresponding to the "rare" codons, while the second requires chemical synthesis of genetic sequences in which the majority of "rare" codons have been replaced with E. coli preferred codons [9] . SARS-CoV2 viral sequences have been published by research teams from several countries [10] [11] [12] , and as of July 18, 2020, research teams from Taiwan alone have published 32 SARS-CoV2 genome sequences. In this study, we referenced the N protein and S protein coding sequences from this publicly available viral genomic data and proceeded to modify the codons based on E. coli preference. The original coding sequence for the SARS-CoV2 N protein and the codon-modified coding sequence of the S protein were chemically synthesized by Genomics (New Taipei City, Taiwan) and then cloned into an E. coli expression system. E. coli with modified N protein coding sequences were obtained from pET15b-NE cloned by the Academia Sinica. The viral protein production capacity of cloned E. coli expression systems was subsequently tested, and the reactivity of these purified viral proteins with patient sera was also assessed. The results indicated that E. coli expression systems were capable of expressing sufficient levels of viral proteins that could be used to develop rapid and accurate diagnostic tests.

The bacterial strains and plasmids used in this study are described in [Table 1 ].

The primers used in this study are listed in [ Table 2 ].

DH5α/pUC57-SE [ Table 1 ] served as the template for the amplification of codon-modified S protein domain DNA fragments by colony polymerase chain reaction (PCR). DH5α/pET15b-NE [ Table 1 ] served as the template for amplification of codon-modified N protein coding sequences. The PCR products of different coding sequences were generated with equal amounts of Pfu and Taq DNA polymerase to reduce mutation rates following amplification. The PCR products of each DNA fragment were cloned into the respective restriction enzyme sites in pQE80L (Qiagen, Hilden, Germany) to generate the expression plasmids, pNE, pSE, pSE-NTD, pSE-RBD, pSE-R3, and pSE-S2 [ Table 2 ]. After transformation, potential clones were evaluated with a previously described rapid screening method [13] , followed by sequencing analysis (Genomics).

To express viral proteins, transformants of each respective recombinant plasmid were expanded at 37°C by inoculating a 0.5-mL overnight culture into 50 mL of LB medium containing ampicillin. Incubation was continued at 37°C until the culture reached an OD 600 of 0.6. Protein expression was induced by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM or 1 mM. After incubating for 3 h at 37°C, cells were harvested by centrifugation at 4,000 × g for 15 min. The cells were then stored at − 80°C until use.

Protein purification was performed by a method described previously [14] . Frozen cells overexpressing target proteins were suspended in 10 mL of 1× binding buffer containing 5 mM imidazole, 0.5 mM NaCl, and 20 mM Tris-HCl (pH 8.0), and subjected to 3 cycles of freezing and thawing at −80°C and room temperature, respectively. The thawed cells were disrupted by sonication at 4°C using a Microson ultrasonic cell disruptor (Misonix, Farmingdale NY, USA). Cell extracts were separated from the cell debris by centrifugation at 17,000× g for 30 min at 4°C (Avanti J-25 Centrifuge, JA25.5 rotor; Beckman Coulter, Brea CA, USA). Recombinant proteins were then purified from the cell extract using Ni-affinity chromatography (Novagen, Madison WI, USA). Purified fractions were analyzed with different concentrations of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), based on the different molecular weights of each recombinant protein, and stained with Coomassie Brilliant Blue G-250.

Total proteins from bacteria cultured under different conditions were collected and separated by SDS-PAGE, and then transferred to a polyvinylidene difluoride (PVDF) membrane, after which specific antibodies were applied to detect protein expression. Human anti-SARS-CoV2 polyclonal antisera was obtained from Access Biologicals, USA (Mitek, COVID-19 Panel, 2X Panel 1.1, PW: 56435). Human subjects including any gender with age ranged from 18 to 90 years old. The confirmed infection with COVID-19 determined by a positive Roche swab results. Sample collected <10 days and more than 30 days after positive results (https://accessbiologicals.com/news/covid-19/). Goat anti-human IgG Fc (HRP) ab97225 and goat anti-human IgM mu chain (HRP) ab97205 were obtained from Abcam (Cambridge, UK). Anti-His monoclonal antibody was obtained from Santa Cruz Biotechnology (Dallas TX, USA). After blocking the transferred membrane with 5% skim milk in 1×TTBS (0.25% Tween-20, 0.05 M Tris-HCl [pH 7.6], 0.9% NaCl), antiserum at 1:1000 dilution in 1×TTBS was added, followed by incubation at room temperature for 1 

The SARS-CoV2 genome contains about 29,000-30,000 bases, with four primary structural proteins [SEM, and N; Figure 1a ]. These structural proteins are likely to be the main targets of immune responses, and we further broke down larger structural proteins into functional domains to better assess immunogenicity. Based on in silico functional domain analysis and a review of the literature, the S protein coding sequence (3,822 bases) was subdivided into the NTD, RBD, and S2 domain [ Figure 1b ]. Previous research has also shown that Region 3 (R3) of the RBD is functionally important for ACE2 receptor binding [15] , and thus the R3 domain (comprising 135 amino acids) was also examined in this study.

Previous studies have shown that viral sequences may not be properly expressed in E. coli due to codon usage differences with eukaryotic cells [9] . To resolve this issue, we designed sequences for chemical synthesis that replaced the original codons with E. coli preferred codons that still code for the same amino acid. In silico analysis of the codon-optimized NTD coding sequence showed that it shared 72% identity with the original viral sequence [ Figure S1a ], while the codon-optimized RBD, S2 domain, and N protein coding sequences respectively shared 71.1% [ Figure S1b ], 72.9% [ Figure S1c ], and 72.5% [ Figure S1d ] identity with the original viral sequences. The final translated amino acid sequences of all codon-optimized coding sequences shared 100% identity with the original viral amino acid sequences [ Figure S1e and f].

In this study, the Qiagen pQE80L expression system was used to express codon-optimized viral proteins, which were then purified with Ni-affinity chromatography. For the amplification of coding sequences for the S protein and related domains, pUC57-SE was used as a template for colony PCR; while for the amplification of N protein coding sequences, pET15b-NE was used as the template. Primers were designed according to the restriction enzyme sites for cloning the codon-optimized coding sequences of viral proteins into pQE80L [ Table 2 ], and PCR was performed with Pfu and Taq DNA polymerases to ensure that the correct DNA sequences were amplified. PCR conditions were set at the respective melting temperatures for the pair of primers corresponding to each cloned coding sequence.

The sizes of the DNA coding sequences for the NTD, RBD, R3 domain, S2 domain, and N protein are respectively 813 base pairs (bp), 819 bp, 405 bp, 1,800 bp and 1,260 bp [ Figure 2 ]. After restriction enzyme digestion and ligation with pQE80L, the resulting plasmids with insert were checked by electrophoresis following quick screening buffer treatment and colony PCR. Results showed that one transformant (lane 11) of the NTD coding sequence had the correct insertion size [ Figure 3a ], and this was subsequently confirmed by sequencing analysis. Three transformants carrying the correct insert size for the RBD coding sequence were identified [ Figure 3b ], and all were confirmed by sequencing analysis. Seven transformants carrying the correct insert size for the S2 domain coding sequence were identified [ Figure 3c ], of which three clones (lane 2, 5, and 7) were confirmed by sequencing analysis. Four transformants of the R3 domain coding sequence were identified via colony PCR [ Figure 3e ], of which three (lane 4, 6 and 11) were confirmed by sequencing analysis. For transformants of the original viral coding sequence of the N protein, only three transformants were identified out of more than 700 transformants screened, and the insert sequences still differed from the original sequences, perhaps due to codon bias in E. coli. One transformant (lane 13) was obtained and confirmed by sequencing analysis for the codon-optimized N protein coding sequence [ Figure 3d ]. . Previously, a team at the Academia Sinica in Taiwan reported that they used the pET15b plasmid of the pET system (Novagen) to express N protein under induction conditions at 16°C for 10-12 h (personal communication); however, our results show that it is possible to obtain codon-optimized N protein using the pQE80L system (Qiagen) following induction at 37°C for 3 h, suggesting that expression efficiency can be enhanced through codon optimization. These results show that more than 80% of patient sera responded to codon-optimized N protein produced in E. coli, suggesting that this may serve as a suitable antigen for rapid antibody detection tests. For RBD serum tests, anti-RBD IgG was detected in only seven samples out of 15, and anti-RBD IgM was detected in nine samples [ Figure 6 ]. Interestingly, serum samples from patients 9011 and 9013 did not respond to N protein, but contained anti-RBD IgM [ Table 3 ]. For S2 serum tests. 60% of samples contained anti-S2 IgG, but only patient 9099 had a high concentration of anti-S2 IgM [ Figure 7 ]. Taken together, these results suggest that N protein and RBD would constitute a better combination for the construction of rapid antibody detection kit with greater accuracy and efficiency.

To date, many COVID-19 diagnostic kits have been developed for commercial production in other countries around the world, but as there is no commercial benefit for diagnostic kit production in Taiwan due to the low number of cases and excellent control of the pandemic, very few local companies have devoted resources to the development of such kits. However, since the start of the pandemic, the Tzu Chi Foundation has provided financial and healthcare support for many people in different countries, and the development of rapid antibody-based testing kits would not only help to protect Foundation volunteers working to provide relief, but could also be used in areas that lack quantitative reverse transcription PCR facilities to quickly identify the infected and enable the timely quarantine of patients. The use of an E. coli expression system can enable the rapid production of SARS-CoV2 viral proteins in sufficient quantities to support the development of testing kits that can be used by the Tzu Chi Foundation for nonprofit purposes.

Although RT-PCR detection of viral RNA remains the most accurate and sensitive testing method currently available, not all areas have access to the advanced facilities and equipment required to conduct such tests, and rapid antibody or viral protein detection kits would be a better choice in such cases. Previous research has shown that 100% of patients tested positive for antiviral IgG within 19 days, in a study that used magnetic chemiluminescence enzyme immunoassay (MCLIA) for viral-specific antibody detection in 285 patients with COVID-19 [16] . Serological detection will also be very helpful for the diagnosis of putative patients with negative RT-PCR results and for identifying asymptomatic infections and recovered infections. According to our immunoblotting results, codon-optimized N protein demonstrated an 80% positive response in serum samples against which it was tested, and the RBD of the S protein also exhibited a positive response in 50% of tested serum, indicating that these viral proteins produced in E. coli expression systems have strong potential to be used in serological testing kits.

To obtain large amounts of proteins in a short timescale, E. coli expression systems have a strong advantage over other expression systems. Cloning and validation can be completed within two weeks for an E. coli expression system [17] .

However, the absence of posttranslational modification represents a major advantage and defect of E. coli expression systems [18] [19] [20] , and codon bias may lead to truncated products because of premature termination of protein translation [21, 22] . To overcome this issue, we prepared chemically synthesized viral protein coding sequences in which E. coli preferred codons were used. The results showed that these codon-optimized viral proteins were successfully produced and were capable of reacting with patient serum samples.

Previous studies have shown that the N protein of most coronaviruses is expressed abundantly during infection and is highly immunogenic [23, 24] . High levels of IgG antiserum against N protein have been detected in patients with SARS infection [25] , and SARS-specific T-cell proliferation and cytotoxic activity triggered by the N protein were typical T-cell responses in a vaccine developed for SARS [26] . IgM antiserum against the N protein of SARS-CoV2 was detected in 80% of serum samples in this study [ Table 3 ], and most previous studies agreed with our observation that the N 86.6% 80% +: interaction with antibodies, ++: Intense interaction with antibodies. NC: negative control anti-serum. ND: Not determined protein represents a good candidate for antibody detection [8] . Indeed, a previous study has used an N-terminal truncated N protein to produce specific antibodies against SARS N protein with no cross-reactivity with human coronaviruses OC43 and 229E [27] . In the future, we will also seek to generate N-terminal truncated N protein to reduce the possibility of cross-reactivity and improve the accuracy of antibody detection kits.

In conclusion, here we describe an E. coli expression system capable of rapidly and abundantly producing SARS-CoV2 viral proteins from chemically synthesized and codon-optimized sequences. Our results showed that the resulting codon-optimized N protein, RBD, and S2 domain were capable of reacting with patient sera, and have strong potential to be used in rapid and accurate serological tests for COVID-19. 

From SARS to MERS, thrusting coronaviruses into the spotlight

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae

Expression and characterization of an M cell-specific ligand-fused dengue virus tetravalent epitope using Saccharomyces cerevisiae

Understanding the effect of high gas entrance velocity on Chinese hamster ovary (CHO) cell culture performance and its implications on bioreactor scale-up and sparger design

Development of a combined genetic engineering vaccine for porcine circovirus type 2 and "Mycoplasma hyopneumoniae" by a baculovirus expression system

Analysis of preferred codon usage in the coronavirus N genes and their implications for genome evolution and vaccine design

Strategies for optimization of heterologous protein expression in E. coli: Roadblocks and reinforcements

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

Complete genome sequence of a novel coronavirus (SARS-CoV-2) isolate from Bangladesh

Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event

Rapid procedure for detection and isolation of large and small plasmids

Biological roles of indole-3-acetic acid in Acinetobacter baumannii

COVID-19 spike-host cell receptor GRP78 binding site prediction

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

High-level expression of soluble viral structural protein in Escherichia coli

Overcoming challenges for amplified expression of recombinant proteins using Escherichia coli

Recombinant protein expression in Escherichia coli (E. coli): What we need to know

Escherichia coli extract-based cell-free expression system as an alternative for difficult-to-obtain protein biosynthesis

Effects of codon usage and vector-host combinations on the expression of spinach plastocyanin in Escherichia coli

Suppression of the negative effect of minor arginine codons on gene expression; preferential usage of minor codons within the first 25 codons of the Escherichia coli genes

Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients

Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle

Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid

Effects of a SARS-associated coronavirus vaccine in monkeys

Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43

The authors would like to thank Dr. Shun-Ping Huang for providing Human anti-SARS-CoV2 polyclonal antisera was obtained from Access Biologicals (Mitek, COVID-19 Panel, 2X Panel 1.1, PW: 56435) and Professor Ingrid Y Liu for valuable discussions.

This study was funded by Grant No. TCIRP109001-02 from Tzu Chi University to Guang-Huey Lin. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

There are no conflicts of interest.